• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

    2/10/22 8:47:19 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZGNX alert in real time by email
    SC 13G/A 1 tv02284-zogenixinc.htm SCHEDULE 13G/A zogenixinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Zogenix Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  98978L204

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  98978L204

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    42,871

    7.  SOLE DISPOSITIVE POWER

    3,872,922

    8.  SHARED DISPOSITIVE POWER

    85,857

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,958,779

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.07%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Zogenix Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    5959 Horton Street, Suite 500
    Emeryville, CA 94608

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    98978L204

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $ZGNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZGNX

    DatePrice TargetRatingAnalyst
    2/28/2022Outperform → Market Perform
    Northland Capital
    1/19/2022Buy → Hold
    Needham
    12/20/2021$37.00 → $32.00Outperform
    SVB Leerink
    9/9/2021$23.00Buy
    UBS
    8/6/2021$48.00 → $44.00Buy
    Needham
    8/6/2021$42.00 → $37.00Outperform
    SVB Leerink
    More analyst ratings

    $ZGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Smith Michael P closing all direct ownership in the company (withholding obligation)

    4 - ZOGENIX, INC. (0001375151) (Issuer)

    3/9/22 7:19:21 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Breitmeyer James B closing all direct ownership in the company (for tax liability)

    4 - ZOGENIX, INC. (0001375151) (Issuer)

    3/9/22 7:16:42 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Stutts Mary E. to satisfy withholding obligation

    4 - ZOGENIX, INC. (0001375151) (Issuer)

    3/9/22 7:15:11 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZGNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FINTEPLA issued to ZOGENIX INC

    Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-9) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 05/30/2023. Application Category: NDA, Application Number: 212102, Application Classification: REMS

    5/31/23 12:11:20 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FINTEPLA issued to ZOGENIX INC

    Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-6) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 01/03/2023. Application Category: NDA, Application Number: 212102, Application Classification: Labeling

    1/4/23 12:43:03 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FINTEPLA issued to ZOGENIX INC

    Submission status for ZOGENIX INC's drug FINTEPLA (SUPPL-5) with active ingredient FENFLURAMINE HYDROCHLORIDE has changed to 'Approval' on 06/15/2022. Application Category: NDA, Application Number: 212102, Application Classification: Labeling

    6/16/22 4:37:19 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZGNX
    SEC Filings

    View All

    SEC Form 15-12B filed by Zogenix Inc.

    15-12B - ZOGENIX, INC. (0001375151) (Filer)

    3/17/22 8:00:59 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Zogenix Inc.

    EFFECT - ZOGENIX, INC. (0001375151) (Filer)

    3/8/22 12:15:16 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Zogenix Inc.

    EFFECT - ZOGENIX, INC. (0001375151) (Filer)

    3/8/22 12:15:08 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ZGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UCB Completes Acquisition of Zogenix, Inc.

    BRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ:ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up to approximately US $1.9 billion / €1.7 billion*. Charl van Zyl, Executive Vice President, Neurology & Head of Europe/International Markets, UCB, said: "We are very pleased to reach today's milestone at the earliest opportunity

    3/7/22 12:00:00 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

    Two podium and one poster presentation share important new findings on FINTEPLA's safety profile and its impact on non-seizure related benefits for LGS patientsLGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approximately 30,000-50,000 patients in the U.S.1 EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Mee

    3/4/22 8:00:00 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

    Executive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and other autoimmune diseases, today announced Jennifer "J.D." Haldeman has joined the company as Vice President of Commercial Operations. Haldeman brings many decades of executive leadership experience to Immunicom. She has led commercial teams for both private and public companies in the biopharma, diagnostics, and medical device arenas, where she was responsible for launching more than a dozen innovative products. Jennifer spent the first te

    3/1/22 11:35:00 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zogenix downgraded by Northland Capital

    Northland Capital downgraded Zogenix from Outperform to Market Perform

    2/28/22 1:52:35 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zogenix downgraded by Needham

    Needham downgraded Zogenix from Buy to Hold

    1/19/22 2:38:51 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on Zogenix with a new price target

    SVB Leerink reiterated coverage of Zogenix with a rating of Outperform and set a new price target of $32.00 from $37.00 previously

    12/20/21 4:55:58 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZGNX
    Leadership Updates

    Live Leadership Updates

    View All

    Immunicom Appoints Jennifer Haldeman as Vice President of Commercial Operations

    Executive with decades of leadership in biopharma and entrepreneurship to aid global commercialization efforts for Company's Immunopheresis® therapy Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and other autoimmune diseases, today announced Jennifer "J.D." Haldeman has joined the company as Vice President of Commercial Operations. Haldeman brings many decades of executive leadership experience to Immunicom. She has led commercial teams for both private and public companies in the biopharma, diagnostics, and medical device arenas, where she was responsible for launching more than a dozen innovative products. Jennifer spent the first te

    3/1/22 11:35:00 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZGNX
    Financials

    Live finance-specific insights

    View All

    Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

    Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced U.S. Food and Drug Administration acceptance with Priority Review of Supplemental New Drug Application for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Submitted Type II Variation Application to the European Medicines Agency to expand the use of FINTEPLA for LGSSubmitted New Drug Application to Japan's Ministry of Health, Labour & Welfare for the marketing approval of FINTEPLA in Dravet syndromePreviously announced agreement to be acquired by UCB; transaction expected to close in the first half of

    2/28/22 8:00:00 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UCB to acquire Zogenix

    BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ:ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine fo

    1/19/22 1:00:00 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results

    FINTEPLA® net product sales of $21.4 million and total revenue of $22.6 million in the third quarter, representing quarter-over-quarter increases of 22% and 20%, respectivelySubmitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for FINTEPLA in Lennox-Gastaut Syndrome (LGS)Continuing to advance late-stage development programs for FINTEPLA and MT1621 EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update. The Company will host a conferen

    11/4/21 4:05:00 PM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

    SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

    2/14/22 9:05:54 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

    SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

    2/11/22 11:43:17 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zogenix Inc. (Amendment)

    SC 13G/A - ZOGENIX, INC. (0001375151) (Subject)

    2/10/22 8:47:19 AM ET
    $ZGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care